MeiraGTx Reacquires Key XLRP Gene Therapy (bota-vec), Plans Immediate Global Regulatory Filings

summarizeSummary

MeiraGTx Holdings plc has reacquired full rights to bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), from Janssen Pharmaceuticals for an upfront payment of $25 million plus potential milestones and royalties, following positive Phase 3 clinical data. The company plans immediate global regulatory submissions, aiming for a 2027 launch.

check_boxKey Events

• Reacquires XLRP Gene Therapy

  MeiraGTx acquired all interests in botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa (XLRP), from Janssen Pharmaceuticals, Inc. This re-acquisition reverses a prior asset sale.

• Significant Financial Terms

  The deal includes a $25 million upfront cash payment, a $50 million contingent milestone upon U.S. regulatory approval and $250 million in U.S. net sales, and mid-teens royalties on global net sales starting mid-2029.

• Positive Phase 3 Data

  The bota-vec Phase 3 LUMEOS study, despite its primary endpoint not meeting statistical significance, showed statistically significant improvements in retinal function, functional vision under low luminance, and visual function, with 40% of treated patients improving in at least two vision domains.

• Accelerated Commercialization Path

  MeiraGTx intends to immediately pursue global regulatory filings (BLA/MAA) in the U.S., EU, and Japan, targeting a potential launch in 2027, leveraging its in-house commercial manufacturing capabilities.

auto_awesomeAnalysis

This 8-K signals a significant strategic move for MeiraGTx, bringing a late-stage gene therapy asset with substantial market potential back into its direct control. The re-acquisition of bota-vec for X-linked retinitis pigmentosa (XLRP), supported by positive Phase 3 data and a clear path to regulatory filings and commercialization, positions the company for a potential product launch in 2027. The upfront payment of $25 million, along with future contingent payments and royalties, represents a material investment for the company, reflecting strong confidence in the asset's value and commercial prospects. This development, coupled with the company's in-house manufacturing capabilities and the stock trading near its 52-week high, could be a major catalyst for future growth and commercialization. The amendment to the Hologen collaboration provides further clarity on existing partnerships and funding.